Get started
Novo Nordisk A/S Sponsored ADR Class BNovo Nordisk A/S Sponsored ADR Class BNovo Nordisk A/S Sponsored ADR Class B

Novo Nordisk A/S Sponsored ADR Class B

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsOptionsBondsETFs

Chart


Full chart

Key facts today


Novo Nordisk will not raise its bid for Metsera after Pfizer's $10 billion acquisition was approved, causing a 1.4% drop in its U.S. shares to $49.54.
Novo Nordisk has entered into a $2.1 billion asset purchase agreement with Omeros, which includes an upfront payment of $240 million anticipated in the fourth quarter of 2025.
Novo Nordisk faces shareholder unrest as minority investors protest a board shake-up by the Novo Nordisk Foundation. Novo Holdings will not suggest a replacement for Dolsten at the next meeting.
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪215.40 B‬ USD
Dividend yield (indicated)
2.45%
Price to earnings Ratio (TTM)
14.32
Basic EPS (TTM)
3.44 USD
Net income (FY)
‪14.65 B‬ USD
Revenue (FY)
‪42.12 B‬ USD
Shares float
‪3.37 B‬
Beta (1Y)
1.38

About Novo Nordisk A/S Class B


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Maziar Mike Doustdar
Website
novonordisk.com
Headquarters
Bagsværd
Founded
1923
ISIN
US6701002056
FIGI
BBG000BQBKR3
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NVO.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

Community forum



See all minds 

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


N
XS300255582
Novo Nordisk Finance (Netherlands) BV 3.625% 27-MAY-2037
Yield to maturity
3.69%
Maturity date
May 27, 2037
N
XS282046075
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2034
Yield to maturity
3.34%
Maturity date
May 21, 2034
N
XS300255353
Novo Nordisk Finance (Netherlands) BV 3.125% 27-MAY-2033
Yield to maturity
3.16%
Maturity date
May 27, 2033
N
XS282045567
Novo Nordisk Finance (Netherlands) BV 3.25% 21-JAN-2031
Yield to maturity
2.95%
Maturity date
Jan 21, 2031
N
XS300255329
Novo Nordisk Finance (Netherlands) BV 2.875% 27-AUG-2030
Yield to maturity
2.91%
Maturity date
Aug 27, 2030
XS244124704
Novo Nordisk Finance (Netherlands) BV 1.375% 31-MAR-2030
Yield to maturity
2.76%
Maturity date
Mar 31, 2030
N
XS300255299
Novo Nordisk Finance (Netherlands) BV 2.375% 27-MAY-2028
Yield to maturity
2.66%
Maturity date
May 27, 2028
N
XS282045460
Novo Nordisk Finance (Netherlands) BV 3.125% 21-JAN-2029
Yield to maturity
2.65%
Maturity date
Jan 21, 2029
XS234803042
Novo Nordisk Finance (Netherlands) BV 0.125% 04-JUN-2028
Yield to maturity
2.52%
Maturity date
Jun 4, 2028
N
XS282044994
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2026
Yield to maturity
2.49%
Maturity date
May 21, 2026
XS244933017
Novo Nordisk Finance (Netherlands) BV 1.125% 30-SEP-2027
Yield to maturity
2.34%
Maturity date
Sep 30, 2027

See all NVO bonds 

ETFs


PPH
VanEck Pharmaceutical ETF
Weight
6.36%
Market value
‪71.19 M‬
USD
PVAL
Putnam Focused Large Cap Value ETF
Weight
1.18%
Market value
‪54.24 M‬
USD
AVDE
Avantis International Equity ETF
Weight
0.35%
Market value
‪37.25 M‬
USD
WCMI
First Trust WCM International Equity ETF
Weight
2.26%
Market value
‪16.63 M‬
USD
PID
Invesco International Dividend Achievers ETF
Weight
1.78%
Market value
‪15.81 M‬
USD
LIFE
Evolve Global Healthcare Enhanced Yield Fund
Weight
4.33%
Market value
‪9.38 M‬
USD
LIFE.B
Evolve Global Healthcare Enhanced Yield Fund
Weight
4.33%
Market value
‪9.38 M‬
USD
LIFE.U
Evolve Global Healthcare Enhanced Yield Fund Trust Units USD Unhedged
Weight
4.33%
Market value
‪9.38 M‬
USD
476070
SAMSUNG KODEX Global Obesity Treatment TOP2 Plus ETF Units
Weight
20.41%
Market value
‪9.32 M‬
USD
APIE
ActivePassive International Equity ETF
Weight
0.97%
Market value
‪9.27 M‬
USD
RVER
Trenchless Fund ETF
Weight
9.22%
Market value
‪9.15 M‬
USD

Explore more ETFs 

Sparks


Curated watchlists where NVO is featured.

See all sparks